Home > Insider Trading > Filing (0001140361-21-005267)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1743881	Bridgebio Pharma Inc.	BBIO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1081714	R Henry Kravis	C/O Kohlberg Kravis Roberts &Amp; Co. L.p. 30 Hudson Yards New York NY 10001	No	No	No	No
1081715	R George Roberts	C/O Kohlberg Kravis Roberts &Amp; Co. L.p. 2800 Sand Hill Road, Suite 200 Menlo Park CA 94025	No	No	No	No
1404912	Kkr & Co. Inc.	C/O Kohlberg Kravis Roberts &Amp; Co. L.p. 30 Hudson Yards New York NY 10001	No	No	No	No
1472694	Llp Management Kkr	C/O Kohlberg Kravis Roberts &Amp; Co. L.p. 30 Hudson Yards New York NY 10001	No	No	No	No
1472698	L.p. Partnership Group Kkr	C/O Kohlberg Kravis Roberts &Amp; Co. L.p. 30 Hudson Yards New York NY 10001	No	No	No	No
1743754	Kkr Group Holdings Corp.	C/O Kohlberg Kravis Roberts &Amp; Co. L.p. 30 Hudson Yards New York NY 10001	No	No	No	No
1780408	L.p. Disorder Genetic Kkr	C/O Kohlberg Kravis Roberts &Amp; Co. L.p. 30 Hudson Yards New York NY 10001	No	No	No	No
1780428	Kkr Genetic Disorder Gp Llc	C/O Kohlberg Kravis Roberts &Amp; Co. L.p. 30 Hudson Yards New York, NY 10001	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-02-17	3,450,000	$60.47	31,060,971	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes

Footnotes

This amount represents the $62.50 secondary public offering price per share of common stock of BridgeBio Pharma, Inc. ("Common Stock") less the underwriting discount of $2.03125 per share for shares sold pursuant to an underwritten public offering
The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.
Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.